Registered title, quoted from ClinicalTrials.gov
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07783321, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Trial participants with nasopharyngeal carcinoma confirmed by histopathology and/or cytology, either initially diagnosed with metastatic disease or relapsed after curative-intent treatment;
Inclusion criterion 4
Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
Inclusion criterion 8
Those who have previously received antibody-drug conjugates (ADCs) using topoisomerase I inhibitors as the toxin, or EGFR- and/or HER3-targeting antibodies/ADCs;
Exclusion criterion 3
Those who have received radical radiotherapy, major surgery, or extensive-field radiotherapy within 4 weeks prior to study randomization;
Exclusion criterion 5
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
Inclusion criterion 7
Must have at least one measurable lesion as defined by RECIST v1.1;
Inclusion criterion 6
Diagnosis of active malignancy within 3 years prior to study randomization;
Exclusion criterion 11
Positive for human immunodeficiency virus (HIV) antibodies, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection;
Exclusion criterion 25
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07783321, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and comply with the protocol requirements;
- Age ≥ 18 years;
- Expected survival time ≥ 3 months;
- Trial participants with nasopharyngeal carcinoma confirmed by histopathology and/or cytology, either initially diagnosed with metastatic disease or relapsed after curative-intent treatment;
- Agree to provide tumor tissue samples obtained at or after the diagnosis of recurrent or metastatic disease;
- Must have at least one measurable lesion as defined by RECIST v1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, with left ventricular ejection fraction ≥ 50%;
- Organ function levels must meet the required criteria;
- Urine protein ≤ 1+ or < 1000 mg/24h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy test must rule out pregnancy; they must not be breastfeeding and must use highly effective contraceptive methods throughout the entire treatment period and for 7 months after the last dose. For male trial participants whose partners are women of childbearing potential, adequate barrier contraception must be used throughout the entire treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- Trial participants who have received prior systemic therapy;
- Those who have received prior therapy targeting the mechanism of tumor immuno-oncology;
- Those who have previously received antibody-drug conjugates (ADCs) using topoisomerase I inhibitors as the toxin, or EGFR- and/or HER3-targeting antibodies/ADCs;
- Trial participants who have received systemic immunostimulatory agents within 4 weeks prior to the first dose;
- Those who have received radical radiotherapy, major surgery, or extensive-field radiotherapy within 4 weeks prior to study randomization;
- History of severe cardiac or cerebrovascular disease;
- Those receiving long-term systemic corticosteroid therapy (e.g., prednisone >10 mg/day) prior to the first dose;
- Active autoimmune diseases and inflammatory diseases;
- Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening;
- Prolonged QTc interval, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias;
- Diagnosis of active malignancy within 3 years prior to study randomization;
- Hypertension inadequately controlled by two antihypertensive agents;
- Trial participants with poorly controlled blood glucose;
- History of interstitial lung disease (ILD) requiring steroid therapy, current ILD, or radiation pneumonitis of Grade ≥2;
- Concurrent pulmonary diseases resulting in clinically severe impairment of respiratory function;
- Active central nervous system (CNS) metastases;
- Severe infection occurring within 4 weeks prior to study randomization;
- Trial participants with massive serosal cavity effusion, symptomatic serosal cavity effusion, or poorly controlled serosal cavity effusion;
- Imaging findings indicating tumor invasion or encasement of abdominal, thoracic, or cervical structures;
- Severe, non-healing wounds, ulcers, or bone fractures within 4 weeks prior to signing informed consent;
- Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
- Trial participants with inflammatory bowel disease, history of extensive bowel resection, history of immune-mediated enteritis, intestinal obstruction, or chronic diarrhea;
- Trial participants with a history of allergy to recombinant humanized antibodies or hypersensitivity to the investigational drug;
- History of autologous or allogeneic stem cell transplantation;
- Positive for human immunodeficiency virus (HIV) antibodies, active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection;
- History of severe neurological or psychiatric disorders;
- Receipt of other unapproved investigational drugs or treatments within 4 weeks prior to study randomization;
- Trial participants who plan to receive, or have received, live vaccines within 28 days prior to study randomization;
- Other conditions deemed by the investigator to make the participant unsuitable for participation in this clinical trial due to complications or other circumstances.
Quoted from ClinicalTrials.gov, NCT07783321, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07783321, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.